Centre du Cancer Lausanne - Publications 2001




Home < Centre de recherche < Publications 2010 < Publications 2001

Publications 2010

Publications 2009

Publications 2008

Publications 2007

Publications 2006

Publications 2005

Publications 2004

Publications 2003

Publications 2002

	Publications 2001

Info.onco@chuv.ch

Publications : 2001
1:	Anchisi S, M. Suleiman, L. Perey, M. Stalder, R. Obrist.
		Cancer du sein. Epidémiologie, prévention, chirurgie et radiothérapie des stades précoces, suivi. Forum Med Suisse No 42, 17 Octobre 2001
2:	Anchisi S., M. Stalder, R. Obrist , M. Suleiman, L. Perey.
		Cancer du sein. Les traitements systémiques adjuvants et au stade métastatique. Forum Med Suisse No 44, 31 Octobre 2001.
3:	Ayyoub, M., Migliaccio, M., Guillaume, P., Lienard, D., Cerottini, J. C., Romero, P., Levy, F., Speiser, D. E., and Valmori, D.
		Lack of tumor recognition by hTERT peptide 540-548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing. Eur J Immunol, 31: 2642-2651., 2001.
4:	Borner MM, Dietrich, D, Stupp R, Morant R, Honegger H, Wernli M, Herrmann R, Poestalozzi BC, Saletti P, Hanselmann S, Müller S, Brauchli P, Castiglione-Gertsch M, Goldhirsch, A, Roth AD.
		Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 20:1759-1766, 2002.
5:	Brada M, Hoang-Xuan K, Rampling R, Dietrich P-Y, Dirix LY, Macdonald D, Heimans JJ, Zonnenberg BA, Bravo-Marques JM, Henriksson R, Stupp R, Yue N, Bruner J, Dugan M, Rao S, Zaknoen S.
		Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12:259-266, 2001.
6:	Dearden, C. E., Matutes, E., Cazin, B., Tjonnfjord, G. E., Parreira, A., Nomdedeu, B., Leoni, P., Clark, F. J., Radia, D., Rassam, S. M., Roques, T., Ketterer, N., Brito-Babapulle, V., Dyer, M. J., and Catovsky, D.
		High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood, 98: 1721-1726., 2001.
7:	Dietrich, P. Y., Walker, P. R., Quiquerez, A. L., Perrin, G., Dutoit, V., Lienard, D., Guillaume, P., Cerottini, J. C., Romero, P., and Valmori, D.
		Melanoma patients respond to a cytotoxic T lymphocyte-defined self- peptide with diverse and nonoverlapping T-cell receptor repertoires. Cancer Res, 61: 2047-2054., 2001.
8:	Dormond O, Rüegg C.
		Inhibition of tumor angiogenesis by non-steroidal anti inflammatory drugs : emerging mechanisms and therapeutic perspectives. Drug Res Updates, 4 : 314-321, 2001.
9:	Dormond, O., Foletti, A., Paroz, C., and Ruegg, C.
		NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. Nat Med, 7: 1041-1047., 2001.
10:	Dutoit, V., Rubio-Godoy, V., Dietrich, P. Y., Quiqueres, A. L., Schnuriger, V., Rimoldi D., Lienard, D., Speiser, D., Guillaume, P., Batard, P., Cerottini, J. C., Romero, P., and Valmori, D.
		Heterogeneous T-cell response to MAGE-A10(254-262): high avidity- specific cytolytic T lymphocytes show superior antitumor activity. Cancer Res, 61: 5850-5856., 2001.
11:	Ghanem, G., Loir, B., Morandini, R., Sales, F., Lienard, D., Eggermont, A., and Lejeune, F.
		On the release and half-life of S100B protein in the peripheral blood of melanoma patients. Int J Cancer, 94: 586-590., 2001.
12:	Lejeune, F. J., Kroon, B. B., Di Filippo, F., Hoekstra, H. J., Santinami, M., Lienard, D., and Eggermont, A. M.
		Isolated limb perfusion: the European experience. Surg Oncol Clin N Am, 10: 821-832, ix., 2001.
13:	Leyton L, Schneider P, C. V. Labra, C. Rüegg, A. F.G. Quest and C. Bron (2001)
		Thy-1 binds to integrin b3 on astrocytes and triggers formation of focal contacts. Curr. Biol., 2001, 11:1028-1038.
14:	Perey L, Benhattar J, Peters R, Jaunin P, Leyvraz S.
		High tumour contamination of leukaphereses in patients with small cell carcinoma of the lung : a comparison of immunochemistry and RT-PCR. Br J Cancer. 2001 Nov 30 ; 85 (11) : 1713-21.
15:	Pichert, G, Hsu Schmitz SF, Hess, U, Cerny T, Cogliatti SB, Betticher D, Stupp R, Schmitter D, Stahel RA, Ghielmini M.
		Weekly x 4 induction therapy with anti-CD20 antibody rituximab: Effect on circulation t(14;18)+ follicular lymphoma cells. Clinical lymphoma 1: 293-297, 2001
16:	Pittet, M. J., Speiser, D. E., Lienard, D., Valmori, D., Guillaume, P., Dutoit, V., Rimoldi, D., Lejeune, F., Cerottini, J. C., and Romero, P.
		Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide. Clin Cancer Res, 7: 796s-803s., 2001.
17:	Pittet, M. J., Speiser, D. E., Valmori, D., Rimoldi, D., Lienard, D., Lejeune, F., Cerottini, J. C., and Romero, P.
		Ex vivo analysis of tumor antigen specific CD8+ T cell responses using MHC/peptide tetramers in cancer patients. Int Immunopharmacol, 1: 1235-1247., 2001.
18:	Pittet, M. J., Zippelius, A., Speiser, D. E., Assenmacher, M., Guillaume, P., Valmori, D., Lienard, D., Lejeune, F., Cerottini, J. C., and Romero, P.
		Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases. J Immunol, 166: 7634-7640., 2001.
19:	Puente Navazo M.D., Valmori D, Rüegg C.
		The alternatively spliced domain TnFnIIIA1-A3 of Tenascin-C, an extracellular protein expressed in tumour stroma suppresses T-lymphocyte activation and secretion of TNF and IFN. J. Immunol, 167 : 6431-6440, 2001.
20:	Rüegg C, Dormond D.
		Suppression of tumor angiogenesis by non steroidal anti inflammatory drugs : a new function for old drugs. The Scientific World, 1 : 808-811, 2001.
21:	Romero, P., Dutoit, V., Rubio-Godoy, V., Lienard, D., Speiser, D., Guillaume, P., Servis, K., Rimoldi, D., Cerottini, J. C., and Valmori, D.
		CD8+ T-cell response to NY-ESO-1: relative antigenicity and in vitro immunogenicity of natural and analogue sequences. Clin Cancer Res, 7: 766s-772s., 2001.
22:	Rubio-Godoy, V., Dutoit, V., Rimoldi, D., Lienard, D., Lejeune, F., Speiser, D., Guillaume, P., Cerottini, J. C., Romero, P., and Valmori, D.
		Discrepancy between ELISPOT IFN-gamma secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life. Proc Natl Acad Sci U S A, 98: 10302-10307., 2001.
23:	Stupp R, Dietrich PY, Ostermann-Kraljevic S, Pica A, Maillard I, Maeder P, Meuli R, Janzer R, Pizzolato G, Miralbell R, Porchet, F, Regli L, de Tribolet, N, Mirimanoff, RO, Leyvraz S.
		Promising survival for newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20:1375-1382, 2002
24:	Stupp, R. and Newlands, E.
		New approaches for temozolomide therapy: use in newly diagnosed glioma. Semin Oncol, 28: 19-23., 2001.
25:	Stupp, R., Bodmer, A., Duvoisin, B., Bauer, J., Perey, L., Bakr, M., Ketterer, N., and Leyvraz, S.
		Is cisplatin required for the treatment of non-small-cell lung cancer? Experience and preliminary results of a phase I/II trial with topotecan and vinorelbine. Oncology, 61: 35-41., 2001.
26:	Stupp, R., Gander, M., Leyvraz, S., and Newlands, E.
		Current and future developments in the use of temozolomide for the treatment of brain tumours. The Lancet Oncology, 2: 552-560, 2001.
27:	Valmori, D., Dutoit, V., Rubio-Godoy, V., Chambaz, C., Lienard, D., Guillaume, P., Romero, P., Cerottini, J. C., and Rimoldi, D.
		Frequent cytolytic T-cell responses to peptide MAGE-A10(254-262) in melanoma. Cancer Res, 61: 509-512., 2001.
28:	Vouillamoz-Lorenz S., Bauer J., Lejeune F., Decosterd L.A.
		Validation of an AAS method for the determination of platinum in biological fluids from patients receiving the oral platinum derivative JM 216. J.Pharma. and Biom.Analysis 25: 465-475, 2001.
29:	Zouhair A., Ozsahin M., Schneider D,. Bauer J., Jichlinski P., Roth A., Douglas P., Miralbell R.
		Invasive bladder carcinoma: a pilot study of conservartive treatment with accelerated radiotherapy and concomitant Cisplatin. Int.J.Cancer 96: 350-355, 2001.
30:	ten Hagen, T. L., Eggermont, A. M., and Lejeune, F. J.
		TNF is here to stay--revisited. Trends Immunol, 22: 127-129., 2001.

Dernière modification le 10.06.2008